Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study

Caruso, Salvatore; Rugolo, Salvatore; Agnello, Carmela; Intelisano, Giorgia; Mari, Lucia Di; Cianci, Antonio

doi:10.1016/j.fertnstert.2005.10.043

Cited by 98 publications

(57 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…67 Indeed, it has recently been shown that sildenafil improved sexual function in premenopausal women with diabetes. 68 Thus it appears that certain patient groups may benefit from treatment with PDE5 inhibitors, but further studies are required to confirm this.…”

Section: Pde5 Inhibitors To Treat Urological Diseasementioning

confidence: 99%

PDE5 inhibitors beyond erectile dysfunction

et al. 2007

View full text Add to dashboard Cite

The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds. The safety and high tolerability of PDE5 inhibitors make them an attractive tool to investigate further physiological functions of PDE5, for example the modulation of intracellular cyclic GMP (cGMP) pools. As cGMP is a key component of intracellular signaling this may provide novel therapeutic opportunities beyond ED even for indications in which chronic administration is necessary. The approval of sildenafil for the treatment of pulmonary hypertension in 2005 was a notable success in this area of research. A number of other potential new indications are currently in various phases of preclinical research and development. In recent years, extensive but very heterogeneous information has been published in this field. The aim of this review is to summarize existing preclinical and clinical knowledge and critically discuss the evidence to support potential future indications for PDE5 inhibitors.

show abstract

Section: Pde5 Inhibitors To Treat Urological Diseasementioning

confidence: 99%

PDE5 inhibitors beyond erectile dysfunction

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Before the intervention, the mean of TSH (2.6 ± 1.07) and prolactin levels (10.05 ± 5.27) were normal in both the intervention and control groups. The study results revealed a significant difference between the two groups regarding the mean scores tercourse in women suffering from type I diabetes [22]. In general, desirable sexual response in females is accompanied by increase in vaginal blood flow.…”

Section: Resultsmentioning

confidence: 79%

Effect of sildenafil citrate on women affected by sexual dysfunction referred to health clinics

Zeinalzadeh

Akbarzadeh

Faridi

et al. 2017

fmpcr

View full text Add to dashboard Cite

Background. Female sexual dysfunction is a serious, multifactorial problem which affects women's quality of life. Objectives. This study aimed at assessing the effect of sildenafil citrate on sexual dysfunction among women of reproductive age. Materials and methods. The present randomized clinical trial was conducted on 84 married women between 18 and 40 years old who suffered from sexual dysfunction. The inclusion criteria of the study were being married and between 18-40 years old, obtaining scores ≥ 22 in FSFI, not having a history of hypothyroidism or hyperprolactinemia, and not suffering from dyspareunia or vaginismus. The intervention group was required to consume 50 mg sildenafil citrate 1 hour before sexual intercourse for 5 weeks, and the control group received placebo. FSFI was completed by both study groups before and 5 weeks after the treatment. The data were analyzed through SPSS (v. 18) and paired t-test and independent t-test. Results. Most of the women (67.2%) were between 30 and 40 years old. The study results revealed a significant difference between the two groups regarding the mean scores of sexual desire (p = 0.011), sexual arousal (p = 0.001), lubrication (p = 0.026), orgasm and sexual satisfaction (p < 0.001), and the whole dimension (p < 0.001). Besides, total mean sexual function before and after for the intervention and control groups was 21.1 ± 3.28 vs. 17.22 ± 5.9 (p < 0.001). Conclusion. In this study, sildenafil citrate was effective in enhancing sexual desire, arousal, orgasm, and sexual satisfaction. Of course, more studies need to be conducted on this issue.

show abstract

“…Among diabetic women, the most commonly reported sexual problem is sexual arousal disorder, a condition characterized by inadequate lubrication and swelling in response to sexual excitement. Other manifestations of female sexual dysfunction in this population include diminished libido, decreased clitoral sensation, vaginal dryness, dyspareunia, and orgasmic dysfunction [35]. The mechanisms proposed previously for male sexual dysfunction may apply to women.…”

Section: Diabetes Mellitusmentioning

confidence: 79%

Sexual dysfunction in the medically ill

Somers¹,

Philbrick

2007

Curr Psychiatry Rep

View full text Add to dashboard Cite

Common in the medically ill, sexual dysfunction results from disruption of one or more stages of the sexual response cycle. Increased understanding of sexual pathophysiology and the psychosocial forces whereby diseases impede normal function promotes more informed treatment choices. This review focuses on the pathophysiology, impact, and treatment options of sexual dysfunction in men and women with spinal cord injuries, multiple sclerosis, dementia, hypertension, heart disease, stroke, cancer, and HIV/AIDS.

show abstract

Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study

Cited by 98 publications

References 37 publications

PDE5 inhibitors beyond erectile dysfunction

PDE5 inhibitors beyond erectile dysfunction

Effect of sildenafil citrate on women affected by sexual dysfunction referred to health clinics

Sexual dysfunction in the medically ill

Contact Info

Product

Resources

About